Weber MS - Search Results

1

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. Among authors: weber ms. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.

2

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.

Kretzschmar B, Pellkofer H, Weber MS. Kretzschmar B, et al. Among authors: weber ms. Curr Neurol Neurosci Rep. 2016 Apr;16(4):38. doi: 10.1007/s11910-016-0639-4. Curr Neurol Neurosci Rep. 2016. PMID: 26944956 Review.

3

Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.

Traub J, Traffehn S, Ochs J, Häusser-Kinzel S, Stephan S, Scannevin R, Brück W, Metz I, Weber MS. Traub J, et al. Among authors: weber ms. Brain Pathol. 2019 Sep;29(5):640-657. doi: 10.1111/bpa.12711. Epub 2019 Mar 5. Brain Pathol. 2019. PMID: 30706542 Free PMC article.

4

Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.

Torke S, Pretzsch R, Häusler D, Haselmayer P, Grenningloh R, Boschert U, Brück W, Weber MS. Torke S, et al. Among authors: weber ms. Acta Neuropathol. 2020 Oct;140(4):535-548. doi: 10.1007/s00401-020-02204-z. Epub 2020 Aug 6. Acta Neuropathol. 2020. PMID: 32761407 Free PMC article.

5

Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.

Torke S, Weber MS. Torke S, et al. Among authors: weber ms. Expert Opin Investig Drugs. 2020 Oct;29(10):1143-1150. doi: 10.1080/13543784.2020.1807934. Epub 2020 Aug 19. Expert Opin Investig Drugs. 2020. PMID: 32772592 Review.

6

Targeting B cells in multiple sclerosis.

Sellebjerg F, Weber MS. Sellebjerg F, et al. Among authors: weber ms. Curr Opin Neurol. 2021 Jun 1;34(3):295-302. doi: 10.1097/WCO.0000000000000938. Curr Opin Neurol. 2021. PMID: 33782253 Review.

7

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

Geladaris A, Torke S, Weber MS. Geladaris A, et al. Among authors: weber ms. CNS Drugs. 2022 Oct;36(10):1019-1030. doi: 10.1007/s40263-022-00951-z. Epub 2022 Sep 30. CNS Drugs. 2022. PMID: 36178589 Free PMC article. Review.

8

BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.

Geladaris A, Torke S, Saberi D, Alankus YB, Streit F, Zechel S, Stadelmann-Nessler C, Fischer A, Boschert U, Häusler D, Weber MS. Geladaris A, et al. Among authors: weber ms. Acta Neuropathol. 2024 Apr 24;147(1):75. doi: 10.1007/s00401-024-02730-0. Acta Neuropathol. 2024. PMID: 38656399 Free PMC article.

9

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Menge T, et al. Among authors: weber ms. Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. Drugs. 2008. PMID: 19016573 Review.

10

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.

Menzfeld C, John M, van Rossum D, Regen T, Scheffel J, Janova H, Götz A, Ribes S, Nau R, Borisch A, Boutin P, Neumann K, Bremes V, Wienands J, Reichardt HM, Lühder F, Tischner D, Waetzig V, Herdegen T, Teismann P, Greig I, Müller M, Pukrop T, Mildner A, Kettenmann H, Brück W, Prinz M, Rotshenker S, Weber MS, Hanisch UK. Menzfeld C, et al. Among authors: weber ms. Glia. 2015 Jun;63(6):1083-99. doi: 10.1002/glia.22803. Epub 2015 Mar 2. Glia. 2015. PMID: 25731696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

416 results

Search Page